Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
25
Recruiting, any sponsor type, condition "deep vein thrombosis"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed175
25 trials
Showing 1 to 25, recently updated first.
- REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult ParticipantsPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07213778 · 2,000 participants (planned) · Start Nov 24, 2025 · Primary completion May 17, 2027
Drug: REGN7508; Acetylsalicylic Acid (ASA) and 1 more · For: Symptomatic Venous Thromboembolism (VTE)
Sites: La Mesa, California; Rancho Mirage, California; Riverside, California · 57 sites in all
- Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic CancersPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07493304 · 1,600 participants (planned) · Start Aug 26, 2026 · Primary completion Jul 18, 2031
Drug: REGN7508; Apixaban · For: Venous Thromboembolism (VTE)
Sites: Hialeah, Florida; New York, New York; El Paso, Texas · 14 sites in all
- REGN7508 in Adult Participants for Prevention of Cancer-Associated ThrombosisPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07410117 · 1,120 participants (planned) · Start Mar 9, 2026 · Primary completion Jan 23, 2030
Drug: REGN7508; Placebo · For: Cancer-Associated Thrombosis (CAT)
Sites: Hialeah, Florida; North Miami Beach, Florida; Boston, Massachusetts · 28 sites in all
- DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein ThrombosisPivotal-lookingRecruiting
Inari MedicalIndustry
NCT05701917 · 300 participants (planned) · Start Jan 6, 2023 · Primary completion Jan 31, 2028
Drug: Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. · For: Venous Thromboembolism; Deep Venous Thrombosis; Post-Thrombotic Syndrome
Sites: Scottsdale, Arizona; Tucson, Arizona; Orange, California · 64 sites in all
University of MonastirAcademic, hospital or other
NCT07863115 · 1,500 participants (planned) · Start Sep 1, 2025 · Primary completion Dec 30, 2028
Drug: Low-Molecular-Weight Heparin (LMWH); Direct Oral Anticoagulants (DOACs) · For: Lower Extremity Injuries; Venous Thromboembolism (VTE); Deep Vein Thrombosis and 1 more
Sites: Monastir, Tunisia
Ottawa Hospital Research InstituteAcademic, hospital or other
NCT06603870 · 330 participants (planned) · Start Dec 19, 2024 · Primary completion Oct 2029
Drug: Anticoagulation Therapy · For: Venous Thromboembolism; Cancer; Upper Extremity Deep Vein Thrombosis and 1 more
Sites: Ottawa, Canada; Sault Ste. Marie, Canada
Al-Nahrain UniversityAcademic, hospital or other
NCT06729021 · 112 participants (planned) · Start Jan 20, 2025 · Primary completion Jul 20, 2027
Drug: LMWH · For: DVT - Deep Vein Thrombosis
Sites: Baghdad, Iraq
- The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue MorbidityPivotal-lookingRecruiting
University of CalgaryAcademic, hospital or other
NCT06494878 · 8,805 participants (planned) · Start Jun 4, 2026 · Primary completion Sep 2030
Drug: Aspirin; Low-molecular-weight heparin · For: Venous Thromboembolism; Postpartum Period; Aspirin and 1 more
Sites: Brussels, Belgium; Calgary, Canada; Ottawa, Canada · 12 sites in all
- Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial)Pivotal-lookingRecruiting
Ottawa Hospital Research InstituteAcademic, hospital or other
NCT06440694 · 150 participants (planned) · Start Jul 7, 2025 · Primary completion Dec 1, 2027
Drug: Colchicine 0.5 mg po; Placebo 0.5 mg po · For: Venous Thromboembolism
Sites: Ottawa, Canada; Windsor, Canada; Montreal, Canada · 4 sites in all
- RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTingPivotal-lookingRecruiting
University Hospital, AngersGovernment (non-federal)
NCT06195540 · 1,424 participants (planned) · Start Jul 19, 2024 · Primary completion Nov 19, 2028
Drug: Rivaroxaban 10 MG; Low Heparin Molecular Weight · For: Venous Thromboembolism; Deep Vein Thrombosis; Pulmonary Embolism and 3 more
Sites: Agen, France; Angers, France; Argenteuil, France · 37 sites in all
- Catheter-Related Early Thromboprophylaxis With Enoxaparin StudiesPivotal-lookingRecruiting
Yale UniversityAcademic, hospital or other
NCT04924322 · 258 participants (planned) · Start May 11, 2022 · Primary completion Apr 30, 2027
Drug: Enoxaparin · For: Deep Venous Thrombosis
Sites: Birmingham, Alabama; Little Rock, Arkansas; Aurora, Colorado · 22 sites in all
- Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking AntiplateletsPivotal-lookingRecruiting
Centre Hospitalier Universitaire de Saint EtienneAcademic, hospital or other
NCT05627375 · 1,400 participants (planned) · Start Aug 16, 2023 · Primary completion Dec 2027
Drug: Full-dose anticoagulant therapy (AC); Antiplatelet therapy (AP) · For: Venous Thromboembolic Disease
Sites: Amiens, France; Angers, France; Besançon, France · 28 sites in all
- Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's SyndromePivotal-lookingRecruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT06780462 · 134 participants (planned) · Start Jun 24, 2025 · Primary completion Dec 24, 2027
Drug: Corticosteroids + Rivaroxaban; Corticosteroids alone · For: Behcet Syndrome
Sites: Bordeaux, France; Boulogne-Billancourt, France; Caen, France · 17 sites in all
- Apixaban in ThrombocytopeniaRecruiting
Rushad PatellAcademic, hospital or other
NCT06886516 · 30 participants (planned) · Start Feb 28, 2025 · Primary completion Jul 1, 2027
Drug: Apixaban · For: Deep Vein Thrombosis; Pulmonary Embolism and Thrombosis; Thrombocytopenia and 1 more
Sites: Boston, Massachusetts
- Timing of Venous Thromboembolism Prophylaxis in Patients With Hypertensive Intracerebral HemorrhagePivotal-lookingRecruiting
Pirogov Russian National Research Medical UniversityAcademic, hospital or other
NCT06753786 · 200 participants (planned) · Start Oct 21, 2024 · Primary completion Dec 31, 2028
Drug: Venous thromboembolism prophylaxis with unfractionated heparin or low molecular weight heparin starting within the first 2 days but not earlier than 12 hours after a hospital admission.; Venous thromboembolism prophylaxis with unfractionated heparin or low molecular weight heparin starting on the 3rd day after a hospital admission. · For: Venous Thromboembolism; Pulmonary Embolism; Intracerebral Hemorrhage and 1 more
Sites: Moscow, Russia
Pirogov Russian National Research Medical UniversityAcademic, hospital or other
NCT03041805 · 3,000 participants (planned) · Start Jan 1, 2017 · Primary completion Jan 1, 2027
Drug: LMWH · For: Venous Thromboembolism; Varicose Veins
Sites: Moscow, Russia
- The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic CancerPivotal-lookingRecruiting
Quercis Pharma AGIndustry
NCT06861088 · 480 participants (planned) · Start Dec 19, 2025 · Primary completion Oct 31, 2027
Drug: Kinisoquin™; Placebo · For: Venous Thromboembolism; Metastatic Pancreatic Cancer; Locally Advanced Pancreatic Adenocarcinoma
Sites: Ventura, California; Miami Lakes, Florida; Boston, Massachusetts
- Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT PreventionPivotal-lookingRecruiting
Mayo Hospital LahoreAcademic, hospital or other
NCT07243080 · 212 participants (planned) · Start Oct 10, 2025 · Primary completion Nov 10, 2025
Drug: rivaroxaban (10mg); Enoxaparin 40 mg SC · For: Deep Venous Thromboses; Laparotomy Patients
Sites: Lahore, Pakistan
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT04694248 · 172 participants (planned) · Start Nov 3, 2021 · Primary completion Dec 31, 2026
Drug: Rivaroxaban; Aspirin · For: Deep Vein Thrombosis; Iliac Vein Thrombosis; Iliac Vein Obstruction and 2 more
Sites: Hangzhou, China
- Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) TrialPivotal-lookingRecruiting
Clinical Urology and Epidemiology Working GroupGovernment (non-federal)
NCT06523959 · 5,436 participants (planned) · Start Jun 6, 2024 · Primary completion Sep 30, 2028
Drug: Apixaban 2.5 MG · For: Venous Thromboembolism; Bleeding
Sites: Helsinki, Finland
Medalp Private Surgery ClinicAcademic, hospital or other
NCT03881345 · 5,000 participants (planned) · Start Apr 1, 2019 · Primary completion Mar 1, 2036
Drug: Anticoagulants · For: Deep Vein Thrombosis; Thromboses, Venous; Thrombosis Embolism and 2 more
Sites: Moscow, Russia
- VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb RevascularizationPivotal-lookingRecruiting
Science Valley Research InstituteAcademic, hospital or other
NCT06873321 · 100 participants (planned) · Start Feb 24, 2024 · Primary completion Jul 20, 2025
Drug: rivaroxaban 2.5 mg bid + aspirin 100 mg; clopidogrel 75 mg od for 3 months followed by aspirin 100 mg od for endovascular procedures or aspirin for open procedures · For: Peripheral Arterial Disease; Venous Thormboembolism; Cardiovascular Diseases and 1 more
Sites: Pernambuco, Brazil
- Pre- Vs Postoperative Thromboprophylaxis for Liver ResectionPivotal-lookingRecruiting
Helsinki University Central HospitalAcademic, hospital or other
NCT04731558 · 1,012 participants (planned) · Start Feb 10, 2021 · Primary completion Feb 2027
Drug: enoxaparin or tinzaparin or dalteparin; No intervention · For: Liver Cancer; Surgery; Thrombosis, Deep Vein and 2 more
Sites: Helsinki, Finland; Kuopio, Finland; Oulu, Finland · 7 sites in all
- ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip ArthroplastyPivotal-lookingRecruiting
Prof. Stavros Konstantinides, MDAcademic, hospital or other
NCT06611319 · 2,932 participants (planned) · Start Nov 26, 2024 · Primary completion Mar 2027
Drug: Prevention of Venous Thromboembolism; Placebo Oral Tablet · For: Hip Arthroplasty, Total; Prevention of Venous Thromboembolism
Sites: Linz, Austria; Kremmen, Germany; Rüsselsheim am Main, Germany · 6 sites in all
- PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST)Pivotal-lookingRecruiting
Sunnybrook Health Sciences CentreAcademic, hospital or other
NCT03559114 · 1,100 participants (planned) · Start Jul 19, 2018 · Primary completion Dec 2026
Drug: Dalteparin; Saline · For: Traumatic Brain Injury
Sites: Calgary, Canada; Edmonton, Canada; Vancouver, Canada · 12 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.